Alzinova’s interim report came without any surprises. The company did a refill on their bank account in Q4. It is encouraging to see that they have a cash position sufficient for the activities they plan to undertake in the coming years. 2021 will be an exciting year. The plan is to take its vaccine candidate into the clinical stage in Q2'21.